Common header menu

Breadcrumb

Urology & Nephrology

Important Notice

This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.

Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

I Agree

Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.(This link opens in a new window)

Urology

Astellas has established a strong presence in the urology area with Harnal®, a treatment for functional symptoms of benign prostatic hyperplasia, as well as overactive bladder treatments Vesicare® and Betanis®/Myrbetriq®/BETMIGA®. We are advancing clinical development by targeting urologic disorders with high unmet medical needs such as Nocturia, Stress urinary incontinence and Underactive bladder.

Nephrology

In nephrology, as a next-generation main product, we are advancing Phase 3 trials of roxadustat in Europe and Japan for anemia associated with chronic kidney disease in patients on dialysis and not on dialysis. In addition, moving forward we will work to develop first-in-class therapies for diabetic nephropathy and continue to challenge other kidney disorders with high unmet medical needs through the drug discovery research focusing on damage for glomerular and renal tubular epithelial cell in kidney.